Estimated annual remaining burden over the years 2012–2112 of HPV-related diseases when vaccinating 12-year old boys and girls versus girls only vaccination aged 12 (cumulative vaccination coverage rate 70%, lifetime duration of protection). Remaining burden of HPV-related cases by subgroup of HPV conditions overtime under either girls-only vaccination or boys and girls vaccination. x-axis : years after implementation; y-axis: remaining number of cases. (A)-male genital warts; (B)- HPV 16/18 related male cancers. Black dotted-lines represent the base line (screening only). Pink lines represent the remaining cases in case of girls-only vaccination. Blue lines represent the remaining cases in case of boys and girls vaccination. Percents given are the relative reduction of incident cases compared with screening alone for a given year: either at 50 years or at 100 years. Over 50 years, (Area Under the Curve), vs. screening only were 32,788 HPV 16/18-related cancers cases and 7.0 million HPV6/11-related genital warts cases, respectively, which would have been avoided in males when vaccinating girls only. Additionally, 52,354 HPV 16/18-related cancers and 9.8 million HPV6/11-related genital warts cases would be avoided when vaccinating boys and girls.